Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
Moertel, Christopher L. , Hirbe, Angela C. , Shuhaiber, Hans, Bielamowicz, Kevin , Sidhu, Alpa , Viskochil, David , Lokku, Armend, Smith, L. Mary, Foreman, Nicholas K. , Hajjar, Fouad, McNall‐Knapp, Rene , Weintraub, Lauren , Antony, Reuben , Franson, Andrea , Schiff, David , Walbert, Tobias , Ambady, Prakash , Bota, Daniela A. , Campen, Cynthia , Kaur, Gurcharanjeet , Maraka, Stefania , Nevel, Kathryn , Aguilar-Bonilla, Ana , Chagnon, Sarah, Dalvi, Nagma , Gupta, Punita , Khatib, Ziad, Metrock, Laura K. , Roberts, Ryan D. , Sadighi, Zsila , Babovic‐Vuksanovic, Dusica , Investigators, for the ReNeu Trial, Raslan, Ahmed M. , Franson, Andrea T., Walter, Andrew , Schiff, David, Hajjar, Fouad M., Slopis, John M. , Klesse, Laura J., Nghiemphu, Leia, Mrugała, Maciej M. , Schmidt, Mary Lou, Foreman, Nick K., Moots, Paul L., Antony, Rueben, Merrell, Ryan , Chagnon, Sarah, Maraka, Stefania, Khatib, Ziad, Foreman, Nicholas K , Franson, Andrea , Meade, Julia , Walbert, Tobias , Klesse, Laura J , Moots, Paul L , Bornhorst, Miriam , Aguilar-Bonilla, Ana , Gupta, Punita , Metrock, Laura K , Nghiemphu, P Leia , Roberts, Ryan D , Babovic-Vuksanovic, Dusica, Gershon, Timothy R , Hirbe, Angela C , Weber, Michael , Klesse, Laura J. , Bornhorst, Miriam , Nghiemphu, Phioanh L. , Robison, Nathan John , Stapleton, Stacie L. , Gershon, Timothy R. , Investigators, for the ReNeu Trial, Franson, Andrea T., Tine, Brian A. Van , Koschmann, Carl , Schiff, David, Hajjar, Fouad M., Capal, Jamie K. , Gill, Jonathan Benjamin , Klesse, Laura J., Kilburn, Lindsay Baker , Foreman, Nick K., Moots, Paul L., Dhamija, Radhika , Antony, Rueben, Chagnon, Sarah, Maraka, Stefania, Khatib, Ziad

Journal of Clinical Oncology | November 8, 2024 | Volume: 43 | Issue: 6 | Pages: 716-729

10.1200/jco.24.01034 | PMID 39514826 Get It

PURPOSE Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration–approved for adults. METHODS ReNeu is an open-label, multicenter, pivotal, phase IIb trial of mirdametinib in 58 adults (≥18 years of age) and 56 children (2 to 17 years of age) with NF1-PN causing significant morbidities. Patients received mirdametinib capsules or tablets for oral suspension (2 mg/m 2 twice daily, maximum 4 mg twice daily), regardless of food intake, in 3 weeks on/1 week off 28-day cycles. The primary end point was confirmed objective response rate (ORR; proportion of patients with a ≥20% reduction of target PN volume from baseline on consecutive scans during the 24-cycle treatment phase) assessed by blinded independent central review (BICR) of volumetric magnetic resonance imaging. RESULTS Twenty-four of 58 adults (41%) and 29 of 56 children (52%) had a BICR-confirmed objective response during the 24-cycle treatment phase; in addition, two adults and one child had confirmed responses during long-term follow-up. Median (range) target PN volumetric best response was –41% (−90 to 13) in adults and –42% (−91 to 48) in children. Both cohorts reported significant and clinically meaningful improvement in patient- or parent proxy-reported outcome measures of worst tumor pain severity, pain interference, and health-related quality of life (HRQOL) that began early and were sustained during treatment. The most commonly reported treatment-related adverse events were dermatitis acneiform, diarrhea, and nausea in adults and dermatitis acneiform, diarrhea, and paronychia in children. CONCLUSION In ReNeu, the largest multicenter NF1-PN trial reported to date, mirdametinib treatment demonstrated significant confirmed ORRs by BICR, deep and durable PN volume reductions, and early, sustained, and clinically meaningful improvement in pain and HRQOL. Mirdametinib was well-tolerated in adults and children.
PRC with Double Interposition Arthroplasty for Failed Partial Wrist Arthrodesis
Cantwell, Susan, Kakar, Sanjeev , Cantwell, Sean R , Kakar, Sanjeev

Journal of Wrist Surgery | November 8, 2024 | Volume: 15 | Issue: 01 | Pages: e29-e33

10.1055/s-0044-1791951 | PMID 41574165 Get It

Abstract In patients with lunate fossa and proximal capitate degeneration, or failed scaphoid excision and partial wrist arthrodesis, double allograft interposition arthroplasty may allow patients to maintain wrist motion and improve pain. Following dorsal exposure of the carpus, a completion proximal row carpectomy is performed. Suture anchors are placed evenly along the perimeter of the distal radius and used to secure a precut sheet of allograft. Additional suture anchors are placed at the proximal aspect of the distal carpal row, securing a second piece of allograft to the proximal capitate and hamate. We present the case of a female with osteogenesis imperfecta who failed prior partial wrist fusion for treatment of scapholunate advanced collapse. She declined wrist arthrodesis and was not a candidate for total wrist arthroplasty. Proximal row carpectomy with double interposition arthroplasty provided resolution of her pain and preserved her wrist range of motion. Double interposition arthroplasty may provide reliable pain relief and wrist range of motion for patients with advanced wrist arthritis in whom traditional salvage procedures are contraindicated or have failed. Use of this technique offers benefits that may minimize complications and improve longevity compared with previously described allograft interposition techniques.
A Multicenter Home-based Prehabilitation Intervention in Kidney Transplant Candidates
Lorenz, Elizabeth C. , Bonikowske, Amanda R. , Meter, Ashley C. David-Van, Munson, Cortney L., Roschen, Callie A., Salstrand, Rosalyn M., Wolter, A , Murthy, B. V. R., Kennedy, Cassie C. , David-Van Meter, Ashley C, Wolter, Anne D, Kennedy, Cassie C , Wolter, Anne D., Davis, LaShara A. , Choi, Namkee G.

Transplantation Direct | November 8, 2024 | Volume: 10 | Issue: 12 | Pages: e1731

10.1097/txd.0000000000001731 | PMID 39534755 Get It

Background. Frailty is a modifiable risk factor for morbidity and mortality among kidney transplant (KT) candidates. We previously demonstrated that an 8-wk center-based exercise intervention is associated with improved frailty parameters in patients with advanced chronic kidney disease. This study aimed to adapt the intervention for home-based delivery and examine its feasibility, safety, and acceptability in a multicenter cohort of KT candidates. Methods. We conducted a prospective pilot study between January 2021 and November 2023 involving KT candidates from Mayo Clinic in Minnesota and Baylor St. Luke’s Medical Center in Texas. Adults approved for KT who were (1) frail or prefrail by the Physical Frailty Phenotype and/or (2) had a Short Physical Performance Battery score ≤10 were enrolled. The exercise intervention consisted of an individualized exercise prescription provided by a Mayo Clinic exercise physiologist followed by 8 weekly phone calls. Feasibility was assessed via retention rates, adverse events were recorded, and acceptability was assessed via survey. Results. Baseline characteristics of the 15 enrolled participants included a median age of 64 y, 73.3% were men, and 73.3% were of White race. Sixty percent of participants completed the intervention. No unanticipated adverse events occurred. Most participants strongly agreed that the exercise intervention was beneficial to their overall health. Conclusions. This pilot study demonstrates that a home-based 8-wk exercise intervention is a promising prehabilitation strategy in KT candidates and provides important preliminary data for future larger, randomized studies.
In-vitro Detection of Intramammary-like Macrocalcifications Using Susceptibility-weighted MR Imaging Techniques at 1.5T
Lebenatus, Annett, Kuster, Josephine Ella, Naujokat, Hendrik , Tesch, Karolin , Jansen, Olav , Ravesh, Mona Salehi , Straub, Sina

Magnetic Resonance in Medical Sciences | November 8, 2024 | Volume: 24 | Issue: 4 | Pages: n/a

10.2463/mrms.mp.2024-0075 | PMID 39523013 Get It

Autologous Serum Tear Production in Anticoagulated Patients
Harrington, M., Su, Leon , Adamski, Jill , Patel, D. , Shusko, Alexander , Shen, Joanne F , Harrington, Maya T, Patel, Dave R, Shusko, Alexander R, Patel, Dave R.

Cornea | November 8, 2024 | Volume: 44 | Issue: 3 | Pages: 373-376

10.1097/ico.0000000000003735 | PMID 39514327 Get It

Purpose: Autologous serum tears (ASTs) are produced from serum obtained by blood draw and used to treat severe dry eye diseases. Multiple cases of failed AST production occurred due to serum becoming a solidified, gel-like substance after centrifugation. The aim of this study was to identify risk factors associated with inability to compound AST. Methods: From January 2019 to December 2022, 99 patients received AST produced at Mayo Clinic in Arizona. Patient demographics, medical diagnoses, medications, laboratory results, and events surrounding blood draws were obtained through an IRB-approved retrospective chart review. The laboratory and pharmacy protocol procedures were observed in person after the occurrence of the last production issue. Results: Ten total clotted serum episodes occurred in 4 patients, each with multiple occurrences. The indication for AST was chronic ocular graft-vs-host disease (n = 3) and Sjögren syndrome (n = 1). Eighty percent of episodes were associated with either a systemic infection (n = 7) or pulmonary embolism (n = 1) within the prior month. At the time of blood draw, all 4 patients were treated with antiplatelet and/or anticoagulation medications, including rivaroxaban, apixaban, aspirin, and low–molecular-weight heparin. Conclusions: The AST protocol was increased from 30 to 60 minutes of resting time to allow clotting before centrifugation. Inadequate clotting during this stasis period likely resulted in fibrinogen remaining suspended in the serum, leading to solidified plasma instead of liquid serum. We hypothesize risk of inadequate clotting would be increased in patients taking anticoagulation or antiplatelet medications. Our recommendations include ensuring 60-minute collection tube resting time for all patients, including those on anticoagulation medication.
Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial
Bruno, Benjamin, Weavil, Joshua C. , Ogle, Jonathan , Chidambaram, Nachiappan, Carey, Elizabeth J. , Danford, Christopher J. , Fricker, Zachary , Galati, Joseph , Lee, William M. , Mantry, Parvez , Shetty, Kirti , DelConte, Anthony , Patel, Mahesh , Bruno, Benjamin J , Lai, Jennifer , Lai, Jennifer C. , Sanyal, Arun J.

Hepatology | November 8, 2024 | Volume: 81 | Issue: 6 | Pages: 1764-1775

10.1097/hep.0000000000001146 | PMID 39513970 Get It

Background and Aims: Sarcopenia is highly prevalent in patients with liver cirrhosis and is associated with adverse clinical outcomes, including HE. Androgen receptor agonists, androgen receptor agonists, can address these conditions through multimodal mechanisms of action; however, their safety and efficacy in patients with cirrhosis have not been well established. Approach and Results: In this multicenter, double-blind, phase 2 trial, men with sarcopenia and cirrhosis awaiting liver transplant were randomized 1:1 to receive either oral Androgen Receptor Agonist LPCN 1148 or placebo for 24 weeks (NCT04874350). The primary end point was the change from baseline to 24 weeks in skeletal muscle index measured by a CT scan of the L3 region, analyzed with a prespecified modified intent-to-treat population. The secondary end point was the number of overt HE events. Twenty-nine participants (mean age=59 y, MELD=17) received at least 1 dose of LPCN 1148 (n=15) or placebo (n=14). Baseline characteristics were similar between groups. Primary end point analysis demonstrated an increase in L3-skeletal muscle index measured by a CT scan of the L3 region in the LPCN 1148 group (n=15) compared to placebo (n=10), with a mean group difference of 4.4 cm2/m2 (95% CI: 1.3–7.4 cm2/m2, p=0.007). Participants in LPCN 1148 experienced fewer episodes of overt HE (Common Terminology Criteria for Adverse Events grade ≥2; p=0.02) than placebo. The number and severity of treatment-emergent adverse events were similar between arms. Conclusions: LPCN 1148 treatment improved sarcopenia and reduced the number of overt HE episodes in men with cirrhosis and sarcopenia awaiting liver transplant. These findings support additional research on the efficacy of LPCN 1148 in treating sarcopenia and preventing HE recurrence.
An AI Model (LORIS) to Predict Immune Checkpoint Blockade Response in Cancer: A Clinical Data Science Perspective
Han, Wenchao, McClintock, David S. , Tavolara, Thomas E, McClintock, David S , Tavolara, Thomas Erol

Clinical Chemistry | November 8, 2024 | Volume: 71 | Issue: 3 | Pages: 345-347

10.1093/clinchem/hvae196 | PMID 39688398 Get It

Occipital Vascularized Bone Graft for Reconstruction of a C3-C7 Defect
Riasa, Nyoman Putu , Reece, Edward M., Kawilarang, Bertha , Jeger, Jonathan L. , Awyono, Steven , Putra, Made Bhuwana , Putra, Kevin Kristian , Suadnyana, I. Putu Ramanda, Mahadewa, Tjokorda Gde Bagus , Jeger, Jonathan L

Plastic and Reconstructive Surgery - Global Open | November 8, 2024 | Volume: 12 | Issue: 11 | Pages: e6268

10.1097/gox.0000000000006268 | PMID 39525885 Get It

Summary: The number of spinal reconstruction cases is growing, as are the accompanying complications. Wound complications after spinal reconstruction can be fatal and can affect up to 19% of patients undergoing major spine surgery. The discipline of spinoplastic surgery is characterized by the use of vascularized bone grafts to reconstruct spinal defects, which provide better results compared with nonvascularized and allogenic equivalents, owing to their superior blood supply. We present a 49-year-old man with spinal defect in the C3-C7 region treated with spinoplastic reconstruction. A 5 × 6 cm occipital VBG was designed with a centrally located muscular pedicle and successfully inset into the osseous defect. Radiographs taken 15 months postoperatively demonstrated overall excellent bony fusion, and the patient made an appropriate clinical recovery. In difficult spine procedures, the use of this occipital vascularized bone graft may lead to higher fusion rates without the need for free tissue transfer or allograft placement, which may not be available at all surgical centers around the world.
Enhanced Recovery Protocol Decreases Postoperative Opioid Use after Penile Inversion Vaginoplasty
Sanchez, Maria V. Rios, Figueroa, Nicole Sanchez, Zheng, Eugene, Leon, Dan Sotelo, Martinez‐Jorge, Jorys, Fahradyan, Vahe , Figueroa, Nicole Gabriela Sanchez , Rios Sanchez, Maria V, Sanchez Figueroa, Nicole, Sotelo Leon, Dan, Sanchez Figueroa, Nicole Gabriela , Fahradyan, Vahe , Leon, Dan Sotelo

Plastic and Reconstructive Surgery - Global Open | November 8, 2024 | Volume: 12 | Issue: 11 | Pages: e6279

10.1097/gox.0000000000006279 | PMID 39525889 Get It

Background: Penile inversion vaginoplasty (PIV) entails considerable soft-tissue dissection to the perineal region and involves complex tissue rearrangement. This study examines the role of an enhanced recovery after surgery (ERAS) pathway after PIV in reducing opioid use and controlling postoperative pain. Methods: A retrospective study of 50 transfemale patients who underwent PIV at a single institution from June 2021 to January 2023 was completed. The study compared 2 groups of patients who were given different postoperative pain management regimens: group A received standard postoperative analgesics and group B received ERAS. Variables such as postoperative pain scores on the numeric pain rating scale (0–10), use of opioid medication, length of hospital stay, and patient comorbidities were recorded and compared across the 2 groups. Results: The average hospital stay length was 4.92 (±0.85) days. Group A had a slightly longer average stay compared with group B. The average pain level in both groups was 4.25 (SD ±1.51). Group A exhibited a slightly higher average pain level of 4.31 (±1.53), whereas group B exhibited 4.16 (SD±1.51) (P = 0.77). Although pain levels did not significantly vary between the 2 groups, there was a statistically significant decrease in the amount of opioid medication used in group B with a P value of 0.009. Conclusions: ERAS protocol is effective in decreasing opioid usage in the immediate postoperative setting after PIV.
Comparing Cochlear Implant Outcomes in 100 Patients With Sporadic Vestibular Schwannoma Managed With Observation, Radiosurgery, or Microsurgery: A Multi-Institutional Review
Dornhoffer, James R. , Marinelli, John P. , Lohse, Christine M. , McMenomey, Sean O., Brown, Kevin D. , Lucas, Jacob C. , Babu, Seilesh C. , Lindquist, Nathan R. , Tan, Donald , Harvey, Erin M. , Deep, Nicholas L. , Cerasiello, Samantha Y., Kircher, Matthew L., Espahbodi, Mana , Tooker, Evan L., Lloyd, Simon , Carlson, Matthew L. , Cottrell, Justin , Roland, J. Thomas , Thompson, Nicholas J. , Perkins, Elizabeth L. , Rahne, Torsten , Plontke, Stefan K. , Hunter, Jacob B. , Harvey, Erin

Otology & Neurotology | November 8, 2024 | Volume: 45 | Issue: 10 | Pages: e719-e726

10.1097/mao.0000000000004298 | PMID 39514427 Get It

Objective To compare cochlear implant (CI) speech perception outcomes in patients with sporadic vestibular schwannoma (VS) managed with observation, radiosurgery, or microsurgery. Study Design Retrospective review. Setting Eleven tertiary academic medical centers. Patients One hundred patients with sporadic VS who received an ipsilateral CI. Interventions Ipsilateral cochlear implantation. Main Outcome Measures Pure-tone thresholds, monosyllabic speech perception testing scores, and rates of open-set speech acquisition. Results Of the 100 patients studied, 54 underwent microsurgery, 26 underwent radiosurgery, 19 continued observation, and 1 underwent multimodal therapy. Among all patients, the median post-implantation pure-tone average was 31 dB (interquartile range [IQR] 25–39 dB) and the median monosyllabic speech perception score was 30% (IQR 0–60%) at a median of 12 months (IQR 5–25 months) post-implantation. Patients who were managed with microsurgery (median speech perception score 11%, IQR 0–52%) exhibited poorer implant outcomes overall compared with those managed with observation (median speech perception score 52%, IQR 40–72%) or radiosurgery (median speech perception score 30%, IQR 16–60%). Open-set speech perception was achieved in 61% of patients managed with microsurgery, 100% with observation, and 80% with radiosurgery. In a multivariable setting, those managed with observation (p = 0.02) or who underwent radiosurgery (p = 0.04) were significantly more likely to achieve open-set speech perception compared with patients who underwent microsurgery. Conclusions Cochlear implants offer benefit in selected patients with sporadic VS. Although achieved in over half of people after microsurgery, open-set speech perception is more reliably attained in patients who are treated with observation or radiosurgery compared with microsurgical resection. These data may inform patient counseling and VS tumor management in people who may benefit from implantation.